Syncona’s late-stage clinical companies have advanced past Phase II clinical trials and working towards delivering potential key value inflection points that have the potential to deliver significant NAV growth, through M&A and liquidity events.
Syncona has a world-leading late-stage clinical portfolio developing products with the potential to treat patients across a range of diseases.
The SIML team has established and built fully integrated companies with best-in-class manufacturing capabilities and world-leading management teams across Syncona’s late-stage clinical companies.
Key facts
Unless stated all financials at 31 December 2025
£372.3m
Value of late-stage clinical portfolio
15
Number of clinical trials
3
Portfolio company Board seats
Our late-stage clinical and commercial companies
Latest late-stage clinical and commercial company insights
Late-stage clinical and commercial company pipeline
Best ideas
Pre-clinical
Clinical
Late Clinical
BLA
